



## Bibliography & Suggested Reading

Alshannaq H, Matuoka J, Pollock RF, et al. Real-time continuous glucose monitoring vs self-monitoring of blood glucose in distinct multi-ethnic cohorts of patients living with insulin-treated type 2 diabetes in the United States: A cost-utility analysis from a Medicare perspective. *J Manag Care Spec Pharm.* 2025;31(8):752-763.

American Diabetes Association (ADA) Professional Practice Committee for Diabetes\*. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. *Diabetes Care.* 2026;49(Supplement\_1):S27-S49.

American Diabetes Association Professional Practice Committee for Diabetes\* . 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. *Diabetes Care.* 2026;49(Supplement\_1):S132-S149.

American Diabetes Association Professional Practice Committee for Diabetes\* . 7. Diabetes Technology: Standards of Care in Diabetes-2026. *Diabetes Care.* 2026;49(Supplement\_1):S150-S165.



American Diabetes Association Professional Practice Committee for Diabetes\* . 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. *Diabetes Care*. 2026;49(Supplement\_1):S339-S355.

Baek JH, Zhu Y, Jackson CL, Park YM. Artificial Light at Night and Type 2 Diabetes Mellitus. *Diabetes Metab J*. 2024;48(5):847-863

Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603.

Beck RW, Raghinaru D, Calhoun P, Bergenstal RM. A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dL. *Diabetes Technol Ther*. 2024;26(3):151-155.

Carlson AL, Martens TW, Johnson L, et al. Continuous Glucose Monitoring Integration for Remote Diabetes Management: Virtual Diabetes Care with Case Studies. *Diabetes Technol Ther*. 2021 ;23(S3):S56-S65.

Centers for Disease Control (CDC). National Diabetes Statistics Report. 2026. Available at: <https://www.cdc.gov/diabetes/php/data-research/index.html>. Accessed April 2026.

Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. *BMJ Open Diabetes Res Care*. 2023;11(5):e003666.

Dhatariya K, Bergenstal RM, Al-Sofiani M, et al. Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology. *Lancet Diabetes Endocrinol*. 2026;14(1):82-92.

ecQI Resource Center. Hospital Harm – Severe Hypoglycemia. Available at: <https://ecqi.healthit.gov/ecqm/hosp-inpt/2025/cms0816v4>. Accessed April 2026.

Edgoose JYC, Quiogue M, Sidhar K. How to Identify, Understand, and Unlearn Implicit Bias in Patient Care. *Fam Pract Manag*. 2019;26(4):29-33.

Ekanayake P, Mudaliar S. A novel hypothesis linking low-grade ketonemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors. *Diabetes Obes Metab*. 2022;24(1):3-11.

Finn E, Schlichting L, Grau L, Douglas IS, Pereira RI. Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital. *Diabetes Care*. 2023;46(10):1825-1830.

Flory JH, Aleman JO, Furst J, Seley JJ. Basal Insulin Use in the Non-Critical Care Setting: Is Fasting Hypoglycemia Inevitable or Preventable? *J Diabetes Sci Technol*. 2014;8(2):427-428.



Huang J, Yeung AM, Bergenstal RM, et al. Update on Measuring Ketones. *J Diabetes Sci Technol*. 2024;18(3):714-726.

Kong YW, Morrison D, Lu JC, et al. Continuous ketone monitoring: Exciting implications for clinical practice. *Diabetes Obes Metab*. 2024;26 Suppl 7(Suppl 7):47-58.

Kumar N, Knight AM, Demidowich AP, et al. Implementing a Continuous Glucose Monitoring Hospital Discharge Program: Strategies and Best Practices. *J Diabetes Sci Technol*. 2026;20(2):299-307.

Morris-Murray M, Frazzitta M. Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure. *J Manag Care Spec Pharm*. 2024;30(10-b Suppl):S30-S39.

National Committee for Quality Assurance (NCQA). Diabetes Recognition Program. Available at: <https://www.ncqa.org/programs/health-care-providers-practices/diabetes-recognition-program-drp/>. Accessed April 2026.

Nguyen KT, Xu NY, Zhang JY, et al. Continuous Ketone Monitoring Consensus Report 2021. *J Diabetes Sci Technol*. 2022;16(3):689-715.

Olsen MT, Klarskov CK, Jensen SH, et al. In-Hospital Diabetes Management by a Diabetes Team and Insulin Titration Algorithms Based on Continuous Glucose Monitoring or Point-of-Care Glucose Testing in Patients With Type 2 Diabetes (DIATEC): A Randomized Controlled Trial. *Diabetes Care*. 2025;48(4):569-578.

Sacks DB, Arnold M, Bakris GL, et al. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. *Clin Chem*. 2023;69(8):808-868.

Selvin E. The Glucose Management Indicator: Time to Change Course? *Diabetes Care*. 2024;47(6):906-914.

Sharma AK, Lee A, Mehta S, et al. Impact of Continuous Glucose Monitor on Health Care Resource Utilization in Adults with Type 2 Diabetes Managed by Noninsulin Therapies. *Diabetes Technol Ther*. 2026;15209156261423934.

Shaw JLV, Bannuru RR, Beach L, et al. Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings. *Diabetes Care*. 2024;47(12):2062-2075.

Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. *Diabetes Care*. 2024;47(8):1257-1275.

Wright EE, Roberts GJ, Chuang JS, et al. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone. *Diabetes Technol Ther*. 2024;26(10):754-762.